Abstract:Oncology drug discovery and development has always been an area facing many challenges. Phase 1 oncology studies are typically small, open-label, sequential studies enrolling a small sample of adult patients (i.e., 3-6 patients/cohort) in dose escalation. Pediatric evaluations typically lag behind the adult development program. The pediatric starting dose is traditionally referenced on the recommended phase 2 dose in adults with the incorporation of body size scaling. The size of the study is also small and dependent upon the prevalence of the disease in the pediatric population. Similar to adult development, the dose is escalated or de-escalated until reaching the maximum tolerated dose (MTD) that also provides desired biological activities or efficacy. The escalation steps and identification of MTD are often rule-based and do not incorporate all the available information, such as pharmacokinetic (PK), pharmacodynamic (PD), tolerability and efficacy data. Therefore, it is doubtful if the MTD approach is optimal to determine the dosage. Hence, it is important to evaluate whether there is an optimal dosage below the MTD, especially considering the emerging complexity of combination therapies and the long-term tolerability and safety of the treatments. Identification of an optimal dosage is also vital not only for adult patients but for pediatric populations as well. Dosage-finding is much more challenging for pediatric populations due to the limited patient population and differences among the pediatric age range in terms of maturation and ontogeny that could impact PK. Many sponsors defer the pediatric strategy as they are often perplexed by the challenges presented by pediatric oncology drug development (model of action relevancy to pediatric population, budget, timeline and regulatory requirements). This leads to a limited number of approved drugs for pediatric oncology patients. This review article provides the current regulatory landscape, incentives and how they impact pediatric drug discovery and development. We also consider different pediatric cancers and potential clinical trial challenges/opportunities when designing pediatric clinical trials. An outline of how quantitative methods such as pharmacometrics/modelling & simulation can support the dosage-finding and justification is also included. Finally, we provide some reflections that we consider helpful to accelerate pediatric drug discovery and development.

Drug Product Development and Case Studies for User Centric Pediatric Protein-Based Therapeutics

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

Paediatric Drug Development and Formulation Design—a European Perspective

Overcoming Challenges in Pediatric Formulation with a Patient-Centric Design Approach: A Proof-of-Concept Study on the Design of an Oral Solution of a Bitter Drug

Pediatric oncology drug development and dosage optimization

An industrial case study: QbD to accelerate time-to-market of a drug product

Defining Patient Centric Pharmaceutical Drug Product Design

State of the art in pediatric nanomedicines

Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?

Food‐Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012‐2022

Assessment of Dosing Strategies for Pediatric Drug Products

Pharmaceutical product development: A quality by design (QbD) approach

Impact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User Centricity

Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children

Nanomedicine Therapies for Pediatric Diseases

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Overcoming Barriers to Drug Development in Children with CKD

Development of Paediatric Medicines: Key Risk Factors and Non-clinical Research Programmes

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Patient Centric Pharmaceutical Drug Product Design—The Impact on Medication Adherence

Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products